Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Valneva Se ADR (NQ: VALN )

6.020 -0.040 (-0.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 33,745
Open 6.080
Bid (Size) 2.440 (2)
Ask (Size) 6.900 (2)
Prev. Close 6.060
Today's Range 6.000 - 6.210
52wk Range 6.000 - 14.49
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Adobe, SelectQuote, Similarweb And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study
Valneva and Pfizer released data from their Phase 2 study of the Lyme disease vaccine candidate VLA15, showing strong immune response and safety profile after a second booster dose, with seroconversion... 
Via Benzinga

Performance

YTD
-41.21%
-41.21%
1 Month
-28.54%
-28.54%
3 Month
-15.21%
-15.21%
6 Month
-18.76%
-18.76%
1 Year
-54.08%
-54.08%

More News

Read More
The Analyst Landscape: 6 Takes On Valneva
Via Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Analyst Scoreboard: 8 Ratings For Valneva
Via Benzinga
What Analysts Are Saying About Valneva Stock
Via Benzinga
The Analyst Landscape: 6 Takes On Valneva
Via Benzinga
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
3 Promising Biotech Stocks You Can Pick Up for Less Than $10
Via InvestorPlace
Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026
Via Benzinga
What Analysts Are Saying About Valneva Stock
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Valneva
Via Benzinga
What Analysts Are Saying About Valneva Stock
Via Benzinga
VALN Stock Earnings: Valneva Misses Revenue for Q4 2023
Via InvestorPlace
Valneva Seeks Expanded Use For Its Chikungunya Vaccine In Adolescents With Encouraging Phase 3 Data
Via Benzinga
VALN Stock Earnings: Valneva Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
Expert Ratings for Valneva
Via Benzinga
Analyst Ratings for Valneva
Via Benzinga
Novavax’s dispute resolution and upcoming earnings call
Via MarketBeat
Topics Earnings
Exposures COVID-19 Financial
Chikungunya Vaccine Maker Valneva Secures Non Dilutive Funding To Develop/Expand Its Clinical Pipeline
Via Benzinga
Exposures Product Safety
McDonald's, Caterpillar And 3 Stocks To Watch Heading Into Monday
Via Benzinga
Valneva Says Single Chikungunya Vaccine Shows Long-Lasting Antibody Response In Younger, Older Adults
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.